MicroDose Therapeutx has initiated a Phase 1 clinical trial of MDT-637, an inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV) that is delivered using the company’s novel dry powder nebulizer. MicroDose is developing MDT-637 in partnership with Gilead Sciences and will develop the product through Phase 2a trials.
The study, which involves 48 healthy adults in the US, is a single ascending dose, randomized, placebo-controlled trial to evaluate the safety, tolerability and pharmacokinetics of MDT-637.
MicroDose Senior Director, Product Commercialization Group Robert Cook commented, “We are pleased to announce first subject dosing as we initiate clinical testing for MDT-637. This study will provide important safety and pharmacokinetic data for assisting dose selection in subsequent clinical development.”
Read the MicroDose press release.
